A crossover study to investigate the relative bioavailability and the effect of food on the pharmacokinetics of a single dose of S-888711 in healthy male subjects

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224619

Enrollment

Registered

2019-03-28

Start date

2008-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

investigational material(s) Generic name etc : lusutrombopag INN of investigational material : lusutrombopag Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy adult male subjects between the ages >=20 and <40

Exclusion criteria

Exclusion criteria: The subject who has a history of nervous, gastric, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, hematic, and other clinically important disorder and is judged as an ineligible by the investigator or subinvestigator. The subject whose family has a history of hematic disorder.

Design outcomes

Primary

Measure	Time frame
bioavailability pharmacokinetics maximum plasma concentration (Cmax), time to reach Cmax (Tmax), area under the plasma concentration-time curve (AUC), terminal elimination half-life (t1/2,z), apparent total clearance (CL/F), and mean residence time (MRT)	—

Secondary

Measure	Time frame
safety Adverse events (AEs), clinical laboratory tests, blood pressure, pulse rate, respiratory rate, body temperature, and ECG parameters	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026